New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl

… any grade in greater than 10% of patients in either the treatment or placebo arm were fatigue, diarrhea, asthenia, nausea, dizziness, and back pain.
Source: back pain